950140 — Englewood Lab Income Statement
0.000.00%
- KR₩199bn
- KR₩191bn
- $133.59m
- 47
- 50
- 46
- 45
Annual income statement for Englewood Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 116 | 141 | 117 | 158 | 134 |
Cost of Revenue | |||||
Gross Profit | 21.3 | 30.1 | 20 | 36.6 | 28.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 110 | 126 | 110 | 136 | 120 |
Operating Profit | 6.69 | 14.8 | 7.65 | 22.1 | 13.8 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4.07 | 13.2 | 6.47 | 22 | 18.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.61 | 13.1 | 5.62 | 15.9 | 14.4 |
Net Income Before Extraordinary Items | |||||
Net Income | 2.61 | 13.1 | 5.62 | 15.9 | 14.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.61 | 13.1 | 5.62 | 15.9 | 14.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.166 | 0.734 | 0.313 | 0.791 | 0.724 |
Dividends per Share |